Why in news?
Union Health Minister J. P. Nadda released the 10th edition of the Indian Pharmacopoeia (IP 2026) in January 2026. This updated volume introduces 121 new monographs and is recognised in 19 countries of the global south. The release underscores India’s efforts to strengthen drug quality standards and enhance pharmacovigilance.
Background
The Indian Pharmacopoeia Commission (IPC) is an autonomous institution under the Ministry of Health and Family Welfare. It became fully operational as an independent body on 1 January 2009, though committees to compile drug standards date back to the colonial era. The IPC’s mission is to promote public and animal health by publishing authoritative standards for the quality of medicines, including active pharmaceutical ingredients, excipients and dosage forms.
The commission develops and revises the Indian Pharmacopoeia—the official book of standards enforced under the Drugs and Cosmetics Act 1940. It also publishes the National Formulary of India, supplies Indian Pharmacopoeia Reference Substances (IPRS) and serves as the National Coordination Centre for the Pharmacovigilance Programme of India (PvPI). Monographs in the pharmacopoeia describe the identity, purity and strength of drugs, including modern medicines, traditional herbal drugs and biological products.
Features of Indian Pharmacopoeia 2026
- The 10th edition adds 121 new monographs, bringing the total to 3,340. New entries include anti‑tuberculosis, anti‑diabetic and anti‑cancer medicines as well as iron supplements.
- For the first time, 20 blood component monographs related to transfusion medicine have been included, following amendments to the Drugs and Cosmetics Rules.
- The pharmacopoeia aligns with international guidelines set by the International Council for Harmonisation and harmonises monographs with European, Japanese and United States pharmacopoeias.
- The Health Minister noted that India’s contribution to the World Health Organization’s pharmacovigilance database improved from 123rd place (2009–2014) to 8th place by 2025, reflecting the IPC’s efforts in drug safety monitoring.
- Indian Pharmacopoeia standards have gained acceptance in 19 countries of the global south, boosting the credibility of Indian medicines abroad.
Objectives and activities of the IPC
- The IPC regularly revises the pharmacopoeia and formulary to reflect technological advances in drug manufacture and analysis.
- It prepares and distributes IPRS materials that act as benchmarks for laboratory testing.
- The commission prioritises monographs for drugs listed in the National List of Essential Medicines and collaborates with pharmacopoeias worldwide to harmonise standards.
- Educational programmes and research activities raise awareness about quality standards and pharmacovigilance among healthcare professionals and the public.
- Through the PvPI, the IPC collects and analyses reports of adverse drug reactions, helping to improve medicine safety.
Conclusion
The release of Indian Pharmacopoeia 2026 marks a milestone in India’s pharmaceutical regulation. By expanding monographs and embracing global harmonisation, the IPC supports the quality, safety and efficacy of medicines. Ongoing education, reference standards and pharmacovigilance programmes will strengthen confidence in the Indian healthcare system.
